FDA approves Hysingla painkiller’s abuse deterrent form
WASHINGTON — The Food and Drug Administration, which last year faced widespread criticism for approving a powerful painkiller that critics said would be easy to misuse, on Thursday OK’d a new form of the drug that will be hard to crush, break or dissolve — tactics used by people trying to ingest large amounts of a drug quickly by snorting or injecting it.
Hysingla ER, an extended-release drug produced by industry giant Purdue Pharma, is the first abuse deterrent alternative to Zohydro ER. Like Zohydro, it is composed of a dose of pure hydrocodone, the main ingredient in Vicodin.
The pure formulation of hydrocodone is designed to allow long-term treatment of chronic pain without posing the risk of liver damage that occurs with additional ingredients such as acetaminophen.
Hysingla is part of a group of drugs known as opioids, which are effective at relieving serious pain but have played a central role in the nation’s epidemic of deaths linked to painkiller addiction.